Hospital for Special Surgery, New York

How normal B cells become leukemic cells

Published in Hospital Law Weekly, June 2nd, 2005

B cell chronic lymphocytic leukemia (CLL) is a disease in which the outcome can be at least partially predicted by whether the patient has mutations in the B cell receptor (BCR) or not, the latter of which predicts the more favorable clinical outcome.

In a study appearing in the June 2005 issue of the Journal of Clinical Investigation, Eric Meffre and colleagues from the Hospital for Special Surgery determine the role of antibody reactivity and the impact of mutations on CLL antibody specificity.

The authors cloned and expressed antibodies from M- and UM-CLL B cells and found that UM-CLL B cells expressed highly reactive antibodies whereas...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hospital Law Weekly

Source: Hospital Law Weekly (2005-06-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry